CD27 and hematologic disorder: A limited number of ongoing clinical trials will amplify the spectrum of therapeutic options in PBL and other rare hematologic malignancies investigating the efficacy of novel agents such as the anti-CD27 antibody varlilumab (NCT03038672) or the BCMA-directed antibody-drug conjugate belantamab mafodotin (NCT04676360).